Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FDQDS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,095
Award facts
- Contract value 100% obligated
- $3,094.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes. The award was issued on October 22, 2025, with an ultimate completion date of November 13, 2025, with performance to be conducted in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The company is headquartered in the same location as the place of performance and has maintained SAM registration since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying indefinite delivery contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's established performance on numerous delivery orders for diverse pharmaceutical products, including specialty biologics and oncology treatments, demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FDQDS?
SPE2DB26FDQDS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DB26FDQDS worth?
The government has obligated $3,095 on SPE2DB26FDQDS.
Is contract SPE2DB26FDQDS an order under another contract?
Yes. SPE2DB26FDQDS is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDS competed?
The extent of competition for SPE2DB26FDQDS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award